Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20–21 September 2019
Richard M. Lee‐Ying(Alberta Health Services), Corinne Doll(University of Calgary), Karen Mulder, Shahida Ahmed(CancerCare Manitoba), Duc Le(University of Saskatchewan), Janine M. Davies(Australian Wildlife Conservancy), Bryan Brunet(University of Saskatchewan), Shahid Ahmed(Emory University), Laura A. Dawson(Princess Margaret Cancer Centre), Pamela Hebbard(University of Manitoba), Oliver F. Bathe(University of Calgary), John Paul McGhie(BC Cancer Agency), Osama Ahmed(University of Saskatchewan), Michael K.C. Lee(BC Cancer Agency), Christina Kim, Vincent C. Tam(University of Calgary), Jessica Kasnik(Alberta Health Services), Howard J. Lim(BC Cancer Agency), Jason Y. Park(Southwestern Medical Center), Ralph Wong(CancerCare Manitoba), Adnan Zaidi(University of Saskatchewan), Daniel J. Renouf(BC Cancer Agency), Valerie Gordon(CancerCare Manitoba), Robin Visser(University of Manitoba)
Cited by 2
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway
|Mucosal Immunology|2014|1.2k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841